High tumor mutation burden is associated with poor clinical outcome in egfr-mutated lung adenocarcinomas treated with targeted therapy

HIGHLIGHTS

• who: Ji-Youn Sung and colleagues from the Department of Pathology, College of Medicine, Kyung Hee University, Seoul, Korea have published the research: High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy, in the Journal: Biomedicines 2022, 2109 of /2022/
• what: The authors aimed to determine the possible predictive or prognostic value of TMB in patients with EGFR-mutant lung adenocarcinoma that were treated with first-line TKIs. The eighth edition of the TNM staging system of lung cancer by the International Association for the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.